Pediatric brain tumors are characterized by frequent complications due to intractable epilepsy compared to adult brain tumors. However, the genetic cause of refractory epilepsy in pediatric brain tumors has not been elucidated yet, and it is difficult to treat patients because the tumors do not respond to existing antiepileptic drugs and debilitate children’s development.
A research team led by Professor Jeong Ho Lee of the Graduate School of Medical Science and Engineering has recently identified a neuronal BRAF somatic mutation that causes intrinsic epileptogenicity in pediatric brain tumors. Their research results were published online in Nature Medicine on September 17.
The research team studied patients’ tissue diagnosed with ganglioglioma (GG), one of the main causes of tumor-associated intractable epilepsy, and found that the BRAF V600E somatic mutation is involved in the development of neural stem cells by using deep DNA sequencing. This mutation was carried out in an animal model to reproduce the pathology of GG and to observe seizures to establish an animal model for the treatment of epileptic seizures caused by pediatric brain tumors.
Using immunohistochemical and transcriptome analysis, they realized that the BRAF V600E mutation that arose in early progenitor cells during embryonic brain formation led to the acquisition of intrinsic epileptogenic properties in neuronal lineage cells, whereas tumorigenic properties were attributed to a high proliferation of glial lineage cells exhibiting the mutation. Notably, researchers found that seizures in mice were significantly alleviated by intraventricular infusion of the BRAF V600E inhibitor, Vemurafenib, a clinical anticancer drug.
The authors said, “Our study offers the first direct evidence that the BRAF somatic mutation arising from neural stem cells plays a key role in epileptogenesis in the brain tumor. This study also showed a new therapeutic target for tumor-associated epileptic disorders.”
In collaboration with the KAIST startup company, SoVarGen, the research team is currently developing innovative therapeutics for epileptic seizures derived from pediatric brain tumors. This study was supported by the Suh Kyungbae Foundation (SUHF) and the Citizens United for Research in Epilepsy.
(Figure: Preoperative and postoperative brain MRI (left panel), tumor H&E (right upper panel) and GFAP immunohistochemical (right lower panel) staining images from a patient with ganglioglioma (GG231) carrying the BRAFV600E mutation. The white arrow and the black arrowhead indicate the brain tumor and a dysplastic neuron, respectively.)
KAIST (President Kwang-Hyung Lee) announced on June 16th that President Kwang-Hyung Lee received an honorary doctorate on the 15th, local time, from the Université de Montréal in Canada, one of the largest French-speaking universities in North America. < Image. (from left) Mr. Pierre Lassonde, Chairman of the Board of Polytechnique Montréal, President Maud Cohen of Polytechnique Montréal, President Kwang-Hyung Lee of KAIST, Chancellor Frantz Saintellemy of Uni
2024-06-16KAIST (President Kwang Hyung Lee) announced on June 5th that its Department of Mechanical Engineering has appointed Kwon Ji-yong, a K-Pop star better known as G-Dragon, as a visiting professor. The appointment was officiated at the “Innovate Korea 2024” event held at the KAIST Sports Complex in the morning of the 5th. This appointment was promoted to expand the global competitiveness of Korean culture by applying the latest scientific technology developed from KAIST to K-conte
2024-06-05Materials that can maintain a magnetized state by themselves without an external magnetic field (i.e., permanent magnets) are called ferromagnets. Ferroelectrics can be thought of as the electric counterpart to ferromagnets, as they maintain a polarized state without an external electric field. It is well-known that ferromagnets lose their magnetic properties when reduced to nano sizes below a certain threshold. What happens when ferroelectrics are similarly made extremely small in all direction
2024-05-31< (From left) KAIST President Kwang-Hyung Lee and Merck CEO Matthias Heinzel > KAIST (President Kwang-Hyung Lee) signed a Memorandum of Understanding (MOU) with Merck Life Science (CEO Matthias Heinzel) on May 29 to foster innovation and technology creation in advanced biotechnology. Since May of last year, the two institutions have been discussing multidimensional innovation programs and will now focus on industry-academia cooperation to tackle bioindustry challenges with this MOU a
2024-05-30What if there is a biodegradable packaging material with high performance without leaving microplastics? Plastic pollution presents a global challenge that must be solved. In particular, packaging accounts for 30-50% of the total plastic consumption. While paper packaging is eco-friendly, it lacks crucial functionalities like moisture resistance and strength. Traditional coating materials exacerbate plastic pollution, prompting the need for sustainable alternatives. Polyethylene (PE) and e
2024-05-22